scispace - formally typeset
Search or ask a question
JournalISSN: 1554-7477

Journal of Oncology Practice 

American Society of Clinical Oncology
About: Journal of Oncology Practice is an academic journal. The journal publishes majorly in the area(s): Health care & Cancer. It has an ISSN identifier of 1554-7477. Over the lifetime, 2179 publications have been published receiving 35155 citations. The journal is also known as: JCO Oncology Practice.
Topics: Health care, Cancer, MEDLINE, Breast cancer, Guideline


Papers
More filters
Journal ArticleDOI
TL;DR: Thirteen categories of breast tumor markers were considered, six of which were new for the guideline, and not all applications for these markers were supported, however.
Abstract: Purpose To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer. Methods For the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The Update Committee’s literature review focused attention on available systematic reviews and metaanalyses of published tumor marker studies. In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations. Recommendations and Conclusions

725 citations

Journal ArticleDOI
TL;DR: This guideline update reflects changes in evidence since the previous guideline and recommends combination cytotoxic chemotherapy is recommended, guided by histology, with early concurrent palliative care.
Abstract: Purpose To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer (NSCLC). Methods An Update Committee of the American Society of Clinical Oncology NSCLC Expert Panel based recommendations on a systematic review of randomized controlled trials from January 2007 to February 2014. Results This guideline update reflects changes in evidence since the previous guideline. Recommendations There is no cure for patients with stage IV NSCLC. For patients with performance status (PS) 0 to 1 (and appropriate patient cases with PS 2) and without an EGFR-sensitizing mutation or ALK gene rearrangement, combination cytotoxic chemotherapy is recommended, guided by histology, with early concurrent palliative care. Recommendations for patients in the first-line setting include platinum-doublet therapy for those with PS 0 to 1 (bevacizumab may be added to carboplatin plus paclitaxel if no contraindications); combination or single-agent chemotherapy or palliative care alone for those with PS 2; afatinib, erlotinib, or gefitinib for those with sensitizing EGFR mutations; crizotinib for those with ALK or ROS1 gene rearrangement; and following first-line recommendations or using platinum plus etoposide for those with large-cell neuroendocrine carcinoma. Maintenance therapy includes pemetrexed continuation for patients with stable disease or response to first-line pemetrexed-containing regimens, alternative chemotherapy, or a chemotherapy break. In the second-line setting, recommendations include docetaxel, erlotinib, gefitinib, or pemetrexed for patients with nonsquamous cell carcinoma; docetaxel, erlotinib, or gefitinib for those with squamous cell carcinoma; and chemotherapy or ceritinib for those with ALK rearrangement who experience progression after crizotinib. In the third-line setting, for patients who have not received erlotinib or gefitinib, treatment with erlotinib is recommended. There are insufficient data to recommend routine third-line cytotoxic therapy. Decisions regarding systemic therapy should not be made based on age alone. Additional information can be found at http://www.asco.org/guidelines/nsclc and http://www.asco.org/guidelineswiki. J Clin Oncol 33:3488-3515. © 2015 by American Society of Clinical Oncology

523 citations

Journal ArticleDOI
TL;DR: A multifaceted strategy will be needed to ensure that Americans have access to oncology services in 2020, as no single action will fill the likely gap between supply and demand.
Abstract: Purpose To conduct a comprehensive analysis of supply of and demand for oncology services through 2020. This study was commissioned by the Board of Directors of ASCO. Methods New data on physician supply gathered from surveys of practicing oncologists, oncology fellows, and fellowship program directors were analyzed, along with 2005 American Medical Association Masterfile data on practicing medical oncologists, hematologists/oncologists, and gynecologic oncologists, to determine the baseline capacity and to forecast visit capacity through 2020. Demand for visits was calculated by applying age-, sex-, and time-from-diagnosis-visit rate data from the National Cancer Institute's analysis of the 1998 to 2002 Surveillance, Epidemiology and End Results (SEER) database to the National Cancer Institute's cancer incidence and prevalence projections. The cancer incidence and prevalence projections were calculated by applying a 3-year average (2000–2002) of age- and sex-specific cancer rates from SEER to the US Cens...

484 citations

Journal ArticleDOI
TL;DR: ASCO's update to its antiemetics guideline now includes an evaluation of evidence on complementary antiemetic therapy.
Abstract: ASCO's update to its antiemetics guideline now includes an evaluation of evidence on complementary antiemetic therapy.

483 citations

Network Information
Related Journals (5)
Journal of Clinical Oncology
84.6K papers, 3.7M citations
91% related
Oncologist
5.3K papers, 238.9K citations
89% related
Seminars in Oncology
5.9K papers, 244.6K citations
85% related
Supportive Care in Cancer
8.8K papers, 222.4K citations
84% related
Lancet Oncology
8.1K papers, 745K citations
83% related
Performance
Metrics
No. of papers from the Journal in previous years
YearPapers
202056
2019246
2018215
2017304
2016322
2015183